-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HCP-2102 in Idiopathic (Essential) Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HCP-2102 in Idiopathic (Essential) Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HCP-2102 in Idiopathic (Essential) Hypertension Drug Details: HCP-2102 is under development...
-
Thematic Analysis
Generic Drugs – Physician Perspective – Thematic Intelligence
Reasons to buy the ‘Generic Drugs – Physician Perspective’ thematic intelligence report: Assess healthcare professionals’ attitudes towards generic drugs prescription. Better understand the barriers to the production and uptake of generic medicines. Capture physicians’ opinions on generics substitution. Better understand patients’ preferences. Assess past and future generics uptake. Gain a better understanding of cost consideration when prescribing drugs. Explore the differences across markets. How is our ‘Generic Drugs – Physician Perspective’ report unique from other reports in the market? This...
-
Thematic Analysis
Patient Empowerment – Thematic Intelligence
Reasons to buy the ‘Patient Empowerment’ thematic intelligence report: Assess patients’ health literacy. Understand interactions between patients and HCPs. Capture patients’ opinions on patient empowerment in healthcare. Gain a deeper understanding of shared decision-making. Evaluate patients’ access to disease and treatment information. Explore the role of pharmaceutical companies in empowering patients. How is our ‘Patient Empowerment’ report unique from other reports in the market? This report combines information obtained from secondary sources and primary research with patients suffering from chronic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cabometyx in Bladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cabometyx in Bladder Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cabometyx in Bladder Cancer Drug Details: Cabozantinib s-malate (Cabometyx, Aptimetyx) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HCP-2202 in Gastric Ulcers
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HCP-2202 in Gastric Ulcers report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.HCP-2202 in Gastric Ulcers Drug Details: HCP-2202 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HCP-2202 in Duodenal Ulcer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HCP-2202 in Duodenal Ulcer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.HCP-2202 in Duodenal Ulcer Drug Details: HCP-2202 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HCP-2102 in Idiopathic (Essential) Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HCP-2102 in Idiopathic (Essential) Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.HCP-2102 in Idiopathic (Essential) HypertensionDrug Details:HCP-2102 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HCP-1803 in Idiopathic (Essential) Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HCP-1803 in Idiopathic (Essential) Hypertension report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HCP-1803 in Idiopathic (Essential) Hypertension Drug Details: HCP-1803 is under...
-
Thematic Analysis
Digital Marketing Trends in Non-small Cell Lung Cancer
Digital Marketing Trends in Non-small Cell Cancer Report Overview Merck’s Keytruda.com achieved the highest total traffic across Non-small Cell Lung Cancer (NSCLC) patient sites in the US from October 2022 to September 2023. This was followed by BMS's Opdivo.com and AstraZeneca's Imfinzi.com. Keytruda.com was also supported by the most paid search engine optimization (SEO) at over 7,600 keywords, closely followed by Enhertu.com and Opdivo.com. Overall, the highest proportion of traffic to top branded patient NSCLC websites originated from direct and organic sources. The Digital...
-
Thematic Analysis
Impact of Inflation on the Healthcare Sector, H2 2023 – Thematic Intelligence
Impact of Inflation on the Healthcare Sector Overview The wide availability of COVID-19 vaccines allowed economies and societies to safely reopen. However, factors such as supply-demand imbalance, inflation, recession prospects, market volatility, and geopolitical tensions and conflicts are hampering the economic recovery and growth prospects. These factors will have a reciprocal impact on healthcare services as well in 2024. The Impact of Inflation on the Healthcare Sector, H2 2023 report assesses inflation's impact on the treatment of patients and identifies...